918822-77-2

Upstream product

• 40913-92-6 4-methylsulfonylbenzoyl chloride 
• 7382-40-3 p-methylphenyl thiosemicarbazide 
• 637-60-5 p-tolylhydrazine hydrochloride 

Downstream Products

• 1579938-96-7 C₁₉H₁₈ClN₃O₃S₂ 
• 918824-77-8 C₁₆H₁₅N₃O₂S₂ 
• 1242163-42-3 1-hydroxy-1-(2-(5-(4-(methylsulfonyl)phenyl)-1-p-tolyl-1H-1,2,4-triazol-3-ylthio)ethyl)urea 
• 1242163-49-0 N-hydroxy-N-methyl-3-(5-(4-(methylsulfonyl)phenyl)-1-p-tolyl-1H-1,2,4-triazol-3-ylthio)propanamide 
• 1579938-69-4 C₂₁H₂₃N₃O₄S₂ 
• 1579938-84-3 N-hydroxy-3-(5-(4-(methylsulfonyl)phenyl)-1-p-tolyl-1H-1,2,4-triazol-3-ylthio)propanamide 
• 1369393-80-5 C₁₈H₂₀N₄O₃S₂ 
• 1242163-53-6 C₁₈H₁₈N₄O₃S₂ 

Relevant academic research and scientific papers

Discovery of novel hybrids of diaryl-1,2,4-triazoles and caffeic acid as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase for cancer therapy

Inflammation plays a key role in cancer initiation and propagation. Cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX), two important enzymes in inflammatory responses are up-regulated in various tumor types. Dual inhibition of COX-2 and 5-LOX constitutes a rational concept for the design of more efficacious anti-tumor agents with an improved safety profile. We have previously reported a series of diaryl-1,2,4-triazole derivatives as selective COX-2 inhibitors. Herein, we hybridized the diaryl-1,2,4-triazoles with caffeic acid (CA) which was reported to display 5-LOX inhibitory and anti-tumor activities, affording a novel class of COX-2/5-LOX dual inhibitors as anti-tumor drug candidates. Most of these compounds exhibited potent COX-2/5-LOX inhibitory and antiproliferative activities in vitro. And the most potent compound 22b could significantly inhibit tumor growth in vivo. Furthermore, mechanistic investigation showed that the representative compound 15c blocked cell cycle in G2 phase and induced apoptosis in human non-small cell lung cancer A549 cells in a dose-dependent manner. Our preliminary investigation results would provide new clues for the cancer theatment with COX-2/5-LOX dual inhibitors.

Discovery of potential anti-inflammatory drugs: Diaryl-1,2,4-triazoles bearing N-hydroxyurea moiety as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase

A series of hybrids from diaryl-1,2,4-triazole and hydroxamic acid or N-hydroxyurea were synthesized and evaluated as novel anti-inflammatory agents. The biological data showed that (i) all the compounds showed dual COX-2/5-LOX inhibitory activities in vitro, and 15e showed optimal inhibitory activities (COX-2: IC50 = 0.15 μM, 5-LOX: IC50 = 0.85 μM), (ii) 15e selectively inhibited COX-2 relative to COX-1 with selectivity index (SI = 0.012) comparable to celecoxib (SI = 0.015), (iii) 15e exhibited potent anti-inflammatory activity (inhibition: 54.1%) which was comparable to the reference drug celecoxib (inhibition: 46.7%) in a xylene-induced ear edema assay, and (iv) 15e displayed promising analgesic activity in acetic acid-induced writhing response and hot-plate assay. Finally, a molecular modeling study revealed the binding interactions of 15e with COX-2 and 5-LOX. Our findings suggest that 15e may be a promising anti-inflammatory agent for further evaluation.